Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Items 301–400 of 796
The Merits of FDDNP-PET Imaging in Alzheimer's Disease
Shin, J., Kepe, V., Barrio, J. R., & Small, G. W. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0008 · Cited by 57
“regions [53, 54] or MRI volumes of the medial temporal regions, which many clinicians currently rely upon for diagnostic confirmation of AD [57].”
Self-citationDifferential effects of the ApoE4 genotype on brain structure and function
Matura, S., Prvulovic, D., Jurcoane, A., Hartmann, D., Miller, J., Scheibe, M., O’Dwyer, L., Oertel‐Knöchel, V., Knöchel, C., Reinke, B., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.042 · Cited by 70
Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 60
Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets
Zloković, B. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00150-3 · Cited by 73
Rasgon, N., & Kenna, H. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.004 · Cited by 69
Self-citationNeuroimaging Measures as Endophenotypes in Alzheimer′s Disease
Braskie, M. N., Ringman, J. M., & Thompson, P. M. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/490140 · Cited by 60
“entorhinal cortex [82], and posterior cingulate cortex [15] may be helpful in further elucidating the links between AD and cardiovascular health.”
BackgroundPositron Emission Tomography Diagnosis of Alzheimer's Disease
Coleman, R. E. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.007 · Cited by 65
“The e4 allele of apolipoprotein E (APOE*E4) occurs in 40% of patients who have late-onset AD, but it is found also in patients who have sporadic AD [17–23].”
BackgroundNahas, Z. H., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., Lorberbaum, J. P., Owens, S. D., McGurk, S. R., DeVane, L., & Risch, S. C. (2003) · Neurocase · doi:10.1076/neur.9.3.274.15563 · Cited by 66
“…schizophrenia symptoms (PANSS scores), only seen with donepezil add-on, is intriguing, in light of a recent report linking the increase in brain activation while performing a cognitive task to a compensatory mechanism in genetically predisposed subjects to Alzheimer’s disease (Small et al., 2000).”
BackgroundSelective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits
Larson, M. E., Greimel, S. J., Amar, F., LaCroix, M., Boyle, G., Sherman, M. A., Schley, H., Miel, C., Schneider, J. A., Kayed, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704698114 · Cited by 61
Small, G. W., Siddarth, P., Silverman, D. H. S., Ercoli, L. M., Miller, K. J., Lavretsky, H., Bookheimer, S. Y., Huang, S.-C., Barrio, J. R., & Phelps, M. E. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31818cd3a4 · Cited by 65
Self-citationsiRNA targeted against amyloid precursor protein impairs synaptic activity in vivo
Hérard, A., Besret, L., Dubois, A., Dauguet, J., Delzescaux, T., Hantraye, P., Bonvento, G., & Moya, K. L. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.020 · Cited by 67
Molecular neuroimaging in Alzheimer’s disease
Jagust, W. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.206 · Cited by 63
“These optimistic results have been reported by more than one research group.(52) When a similar approach was used with AD patients, the larger size of metabolic reductions over time resulted in still smaller estimates of necessary sample size—as low as 36 subjects per group to detect a 33% treatment effect with 80% po…”
Genetic Evidence for Cognitive Reserve: Variations in Memory and Related Cognitive Functions
Lee, J. H. (2003) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.25.5.594.14582 · Cited by 57
Cohen, R. M., Podruchny, T. A., Bokde, A. L. W., Carson, R. E., Herscovitch, P., Kiesewetter, D. O., Eckelman, W. C., & Sunderland, T. (2003) · Synapse · doi:10.1002/syn.10225 · Cited by 64
“Because differences have been reported in regional cerebral metabolic rates in APOE- 4 and APOE- 4- subjects (Reiman et al., 1996, 2001; Small et al., 2000), and cerebral blood flow (CBF) is coupled to cerebral metabolic rate, regional CBF was also determined.”
In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains
Hawkinson, T. R., Clarke, H. A., Young, L. E. A., Conroy, L. R., Markussen, K. H., Kerch, K. M., Johnson, L. A., Nelson, P. T., Wang, C., Allison, D. B., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12523 · Cited by 63
Johnson, L. A., Torres, E. R., Weber Boutros, S., Patel, E., Akinyeke, T., Alkayed, N. J., & Raber, J. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17746186 · Cited by 56
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?
Mosconi, L., & McHugh, P. F. (2011) · PubMed · Cited by 74
Gispert, J. D., Rami, L., Sánchez‐Benavides, G., Falcón, C., Tucholka, A., Rojas, S., & Molinuevo, J. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.027 · Cited by 67
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55
“Interestingly, this brain hypometabolism in APOε4 carriers is a gradually progressing process that leads to a further decline after a 2-year period, as shown in followup studies [121,125].”
BackgroundSilverman, D. H. S. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00139-2 · Cited by 55
Self-citationPositron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction
Silverman, D. H. S., Mosconi, L., Ercoli, L., Chen, W., & Small, G. W. (2008) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.02.006 · Cited by 55
Self-citationImaging of Alzheimer's Disease
Lee, B. C. P., Mintun, M., Buckner, R. L., & Morris, J. C. (2003) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2003.tb00179.x · Cited by 55
“with pathologically proved AD in 88% of the cases, with a sensitivity of 94% and specificity of 73%.(101) Similar high”
BackgroundRoffman, J. L., Weiss, A. P., Goff, D. C., Rauch, S. L., & Weinberger, D. R. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600642945 · Cited by 52
PET imaging in the assessment of normal and impaired cognitive function
Silverman, D. H. S., & Alavi, A. A. (2005) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.09.012 · Cited by 55
“lism in posterior cingulate, parietal, and temporal cortex, and have identified greater metabolic asymmetry in nondemented relatives of individuals with probable AD [44–47].”
BackgroundSelf-citationMitochondrial Chaperones in the Brain: Safeguarding Brain Health and Metabolism?
Castro, J. P., Wardelmann, K., Grune, T., & Kleinridders, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00196 · Cited by 53
Impaired Insulin Signaling and Mechanisms of Memory Loss
Bloemer, J., Bhattacharya, S., Amin, R., & Suppiramaniam, V. D. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00013-2 · Cited by 57
Heertum, R. L. V., & Tikofsky, R. S. (2003) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2003.127294 · Cited by 56
LEVY, J. A., BERGESON, J., PUTNAM, K., ROSEN, V., COHEN, R., LALONDE, F., MIRZA, N., LINKER, G., & SUNDERLAND, T. (2004) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617704103044 · Cited by 50
“There is evidence of intact recall of gist information (for prose) in the normal aging process (B.J. Small et al., 1999) and in AD (Johnson et al., 2003).”
BackgroundInfluentialSystemic alterations of tricarboxylic acid cycle enzymes in Alzheimer’s disease
Jia, D., Wang, F., & Yu, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1206688 · Cited by 53
“The susceptible areas of glucose metabolism decline in the brain of AD patients, including the posterior cingulate, parietal, and temporal cortices (Reiman et al., 1996; Small et al., 2000).”
BackgroundAlzheimer’s genes in microglia: a risk worth investigating
Sudwarts, A., & Thinakaran, G. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00679-4 · Cited by 44
“…and temporal cortices are particularly vulnerable to age-related changes in lipid composition [187, 188], and these regions show decreased glucose metabolism in APOE ɛ 4 carriers [189, 190], suggesting that alleles of this lipoprotein may drive region-specificity of dysfunction and pathogenesis.”
BackgroundNeuroimaging in the early diagnosis of neurodegenerative disease
Stoessl, A. J. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-5 · Cited by 61
“Entorhinal cortex hypometabolism also predicts cognitive decline in healthy subjects, particularly those who carry the ApoE4 genotype [73,74].”
BackgroundTriad of Risk for Late Onset Alzheimer’s: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex
Wang, Y., & Brinton, R. D. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00232 · Cited by 52
“Compared to non-carriers, APOEε4 carriers showed reduced cerebral parietal glucose metabolism among cognitive normal elderlies with family history of AD (Small et al., 1995, 2000).”
BackgroundDougherty, R. J., Schultz, S. A., Kirby, T. K., Boots, E. A., Oh, J. M., Edwards, D., Gallagher, C. L., Carlsson, C. M., Bendlin, B. B., Asthana, S., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161067 · Cited by 48
“Additionally, decreased cerebral glucose metabolism is predictive of cognitive decline and conversion to AD among cognitively normal older adults [6, 7].”
Duan, W., Zhou, G. D., Balachandrasekaran, A., Bhumkar, A. B., Boraste, P. B., Becker, J. T., Kuller, L. H., López, O. L., Gach, H. M., & Dai, W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210199 · Cited by 54
In Vivo Brain Imaging of Tangle Burden in Humans
Small, G. W., Agdeppa, E. D., Kepe, V., Satyamurthy, N., Huang, S., & Barrio, J. R. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:19:3:321 · Cited by 53
Self-citationParanjpe, M. D., Chen, X., Liu, M., Paranjpe, I., Leal, J. P., Wang, R., Pomper, M. G., Wong, D. F., Benzinger, T. L. S., & Zhou, Y. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101795 · Cited by 51
ApoE and cerebral insulin: Trafficking, receptors, and resistance
Rhea, E. M., Raber, J., & Banks, W. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104755 · Cited by 47
Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study
Mosconi, L., Sorbi, S., Nacmias, B., Cristofaro, M. T. D., Fayyaz, M., Bracco, L., Herholz, K., & Pupi, A. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2003.12.005 · Cited by 51
Tosun, D., Schuff, N. W., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2015) · Neurodegenerative Diseases · doi:10.1159/000439257 · Cited by 51
Mega, M. S., Small, G. W., Xu, M. L., Felix, J., Manese, M., Tran, N. P., Dailey, J. I., Ercoli, L. M., Bookheimer, S. Y., & Toga, A. W. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00013 · Cited by 49
“Most of these persons have been included in previous work (33, 34).”
BackgroundSelf-citationGaitán, J. M., Boots, E. A., Dougherty, R. J., Oh, J. M., Ma, Y., Edwards, D. F., Christian, B. T., Cook, D. B., & Okonkwo, O. C. (2019) · Brain Plasticity · doi:10.3233/bpl-190093 · Cited by 49
“While asymptomatic individuals with genetic and familial history of AD face increased risk of developing AD [15, 16], it also remains unknown whether aerobic exercise training modulates CRF and outcomes associated with AD among such individuals.”
BackgroundVisualizing Pathology Deposits in the Living Brain of Patients with Alzheimer's Disease
Kepe, V., Huang, S., Small, G. W., Satyamurthy, N., & Barrio, J. R. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)12010-8 · Cited by 49
Self-citationCerebrometabolic abnormalities in Alzheimer's disease
Blass, J. P. (2003) · Neurological Research · doi:10.1179/016164103101201995 · Cited by 49
Temporally Graded Activation of Neocortical Regions in Response to Memories of Different Ages
Woodard, J. L., Seidenberg, M., Nielson, K. A., Miller, S. K., Franczak, M., Antuono, P., Douville, K. L., & Rao, S. M. (2007) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2007.19.7.1113 · Cited by 45
“The right fusiform region has been associated with face recognition and processing (Sperling et al., 2001, 2003; Bernstein, Beig, Siegenthaler, & Grady, 2002) and may be involved in processing specific features of visual objects (Garoff, Slotnick, & Schacter, 2005; Simons, Koutstaal, Prince, Wagner, & Schacter, 2003;…”
BackgroundMishra, A., Wang, Y., Yin, F., Vitali, F., Rodgers, K. E., Soto, M., Mosconi, L., Wang, T., & Brinton, R. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101542 · Cited by 60
Hartl, D., Schuldt, V., Forler, S., Zabel, C., Klose, J., & Rohe, M. (2012) · Journal of Proteome Research · doi:10.1021/pr300021e · Cited by 48
Arendt, T., Stieler, J., & Holzer, M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1342-8 · Cited by 49
Going round in circles—The Papez circuit in Alzheimer's disease
Forno, G., Lladó, A., & Hornberger, M. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15494 · Cited by 52
“Interestingly, in APOE4 carriers reduced PCC glucose metabolic rates have been associated with greater memory impairment (Small et al., 2000).”
BackgroundLavretsky, H., Ercoli, L., Siddarth, P., Bookheimer, S., Miller, K., & Small, G. (2003) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.11.6.667 · Cited by 52
Self-citationGaertner, R. F., Wyss-Coray, T., Von Euw, D., Lesné, S., Vivien, D., & Lacombe, P. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.008 · Cited by 46
Imaging genetic influences in human brain function
Mattay, V. S., & Goldberg, T. E. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.03.014 · Cited by 49
“Early resting studies also found widespread reductions in glucose metabolism in otherwise normal APOE e4 carriers [44,45].”
BackgroundMagnetic resonance and PET studies in the early diagnosis of Alzheimer’s disease
Mosconi, L., De Santi, S., Rusinek, H., Convit, A., & de Leon, M. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.831 · Cited by 46
Alcohol Intoxication and Cognition: Implications on Mechanisms and Therapeutic Strategies
Jacob, A., & Wang, P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00102 · Cited by 53
Li, W., Antuono, P., Xie, C., Chen, G., Jones, J. L., Ward, B. D., Singh, S. P., Franczak, M. B., Goveas, J. S., & Li, S. (2014) · Cortex · doi:10.1016/j.cortex.2014.04.006 · Cited by 50
Dubelaar, E. J. G., Verwer, R. W. H., Hofman, M. A., Van Heerikhuize, J. J., Ravid, R., & Swaab, D. F. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.159 · Cited by 45
“A 2-year-interval period in cognitively normal subjects who were at risk for AD resulted in a regional cerebral glucose metabolic decline in the left posterior cingulate region and the inferior parietal and lateral temporal regions only in those subjects carrying an apoE «4 allele and not the non-carriers (34).”
BackgroundBrainerd, C. J., Reyna, V. F., Petersen, R. C., Smith, G. E., & Taub, E. S. (2011) · Neuropsychology · doi:10.1037/a0024483 · Cited by 51
“cortical metabolic rates (Small et al., 2000), and reductions in”
BackgroundHawkins, K. M., Goyal, A. I., & Sergio, L. E. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142079 · Cited by 50
“Earlier studies have also demonstrated reduced glucose metabolism in parietal and temporal areas of ApoE4 carriers over the age of 50 with AD affected relatives [56–58].”
BackgroundPET imaging in neurology: Alzheimer’s and Parkinson’s diseases
Sarikaya, İ. (2015) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000320 · Cited by 47
Nielsen, H. M., Chen, K., Lee, W., Chen, Y., Bauer, R. J., Reiman, E., Caselli, R., & Bu, G. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0231-9 · Cited by 44
Mahley, R. W. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102684 · Cited by 43
Apolipoprotein- ε 4 is associated with higher fecundity in a natural fertility population
Trumble, B. C., Charifson, M., Kraft, T. S., García, A. R., Cummings, D. K., Hooper, P. L., Lea, A. J., Rodríguez, D. E., Koebele, S. V., Buetow, K. H., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade9797 · Cited by 47
Strazielle, C., Jazi, R., Verdier, Y., Qian, S., & Lalonde, R. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.08.005 · Cited by 44
Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE ϵ4 carriers
Filippini, N., Zarei, M., Beckmann, C. F., Galluzzi, S., Borsci, G., Testa, C., Bonetti, M., Beltramello, A., Ghidoni, R., Benussi, L., et al. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21757 · Cited by 41
“In particular, functional studies using positron emission tomography (PET) have provided evidence of reduced glucose metabolism rate in prefrontal, posterior cingulated, and parietotemporal regions of young (7) and late middle aged (8) cognitively normal APOE ε4 carriers.”
BackgroundSilverman, D. H. S., Cummings, J. L., Small, G. W., Gambhir, S. S., Chen, W., Czernin, J. G., & Phelps, M. E. (2002) · Molecular Imaging and Biology · doi:10.1016/s1536-1632(02)00016-1 · Cited by 48
Self-citationDowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. J. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.10.050 · Cited by 43
“Previous research (Reiman et al., 2001, 1996; Small et al., 2000) has demonstrated a link between ApoE ε4 carriers and lower cerebral glucose metabolism as compared to ApoE ε4 non-carriers.”
Estrogen use and brain metabolic change in older adults. A preliminary report
Rasgon, N., Small, G. W., Siddarth, P., Miller, K. J., Ercoli, L. M., Bookheimer, S. Y., Lavretsky, H., Huang, S. C., Barrio, J. R., & Phelps, M. E. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00084-1 · Cited by 47
Self-citationMechanisms of memory loss in Aβ and tau mouse models
Ashe, K. H. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330591 · Cited by 42
Wu, X., Lu, J., Chen, K., Long, Z., Wang, X., Shu, H., Li, K., Liu, Y., & Yao, L. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.12.050 · Cited by 42
“…(including Broca's area) participated in semantic retrieval, semantic categorization and other semantic associated conditions (Daselaar et al., 2002; Demb et al., 1995; Demonet et al., 1992; Golby et al., 2005; Koch et al., 2002; Petersen et al., 1988; Small et al., 2000; Thompson-Schill, 2003).”
InfluentialYi, D., Lee, D. Y., Sohn, B. K., Choe, Y. M., Seo, E. H., Byun, M. S., & Woo, J. I. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.12.173 · Cited by 45
LUPIEN, S. J., Lord, C., Sindi, S., Wilkinson, C. W., & Fiocco, A. J. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00097-8 · Cited by 43
Shoghi, K. I., Barrio, J. R., Kepe, V., Wu, H.-M., Small, G. W., Phelps, M. E., & Huang, S. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.02.003 · Cited by 42
“In the end, imaging of Ah and NFT structures should be carefully evaluated in conjunction with other measures of AD progression including cerebral glucose metabolism rates [83–85], neuronal cell loss [86] and activated inflammatory presence [87,88].”
BackgroundSelf-citationWang, Y., Shang, Y., Mishra, A., Bacon, E., Yin, F., & Brinton, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65402-5 · Cited by 42
Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
Kang, S. K., Kim, D., Shin, S. A., Kim, Y. K., Choi, H., & Lee, J. S. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264414 · Cited by 43
Bladowska, J., Zimny, A., Kołtowska, A., Szewczyk, P., Knysz, B., Gąsiorowski, J., Furdal, M., & Sąsiadek, M. J. (2012) · European Journal of Radiology · doi:10.1016/j.ejrad.2012.11.029 · Cited by 41
Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene
Lancaster, T. M., Baird, A. L., Wolf, C., Jackson, M. C., Johnston, S. J., Donev, R., Thome, J., & Linden, D. E. J. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.02.001 · Cited by 41
“signalling observed in association with several AD risk genes and implicated in AD neuropathology (Cowburn et al, 2007; Cheung et al, 2008; Small et al., 2000) may be a factor, but further work on the cellular biology of the CLU risk variant is needed to pursue such a hypothesis.”
Silverman, D. H. S., & Phelps, M. E. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3236 · Cited by 44
Self-citationFDG-PET Contributions to the Pathophysiology of Memory Impairment
Segobin, S. H., Joie, R. L., Ritz, L., Beaunieux, H., Desgranges, B., Chételat, G., Pitel, A., & Eustache, F. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9297-6 · Cited by 42
Axonal Transport and Mitochondrial Dysfunction in Alzheimer's Disease
Riemer, J., & Kins, S. (2013) · Neurodegenerative Diseases · doi:10.1159/000342020 · Cited by 38
Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice
Giannisis, A., Patra, K., Edlund, A. K., Nieto, L. A., Benedicto-Gras, J., Moussaud, S., de la Rosa, A., Twohig, D., Bengtsson, T., Fu, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01548-0 · Cited by 41
“Reduced glucose metabolism in parietal, temporal and posterior cingulate regions, as assessed with FDGPET, was previously linked to APOE ε4 in non-demented subjects, and in subjects at risk of AD [9, 70, 71].”
BackgroundZimny, A., Szewczyk, P., Trypka, E., Wojtynska, R., Noga, L., Leszek, J., & Sasiadek, M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110254 · Cited by 41
“…(PWI) [9–11] or diffusion tensor imaging (DTI) [12–14], indicate affected region in dementia and predementia patients Metabolic reduction in this area is believed to be able individuals, indicating that the pathologic process begins well before even mild dementia is recognized clinically [15].”
The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias
(2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585628940 · Cited by 38
The Use of Biomarkers in the Elderly: Current and Future Challenges
Sunderland, T., Gur, R. E., & Arnold, S. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.016 · Cited by 41
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Ikeuchi, T., Kanda, M., Kitamura, H., Morikawa, F., Toru, S., Nishimura, C., Kasuga, K., Tokutake, T., Takahashi, T., Kuroha, Y., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1040476 · Cited by 39
“In accordance with previous studies (23, 24), participants with one or two alleles of ε4 were defined as the APOE ε4-positive group and those without the ε4 allele as the APOE ε4-negative group.”
MethodImaging studies and APOE genotype in persons at risk for Alzheimer’s disease
Scarmeas, N., & Stern, Y. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0076-1 · Cited by 46
Imaging genetics of schizophrenia in the post-GWAS era
Arslan, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.018 · Cited by 40
Linking Brain Imaging and Genomics in the Study of Alzheimer's Disease and Aging
REIMAN, E. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.011 · Cited by 39
Harrison, T. M., Burggren, A. C., Small, G. W., & Bookheimer, S. Y. (2015) · Human Brain Mapping · doi:10.1002/hbm.23036 · Cited by 41
“At the cellular level, the entorhinal cortex is the first area to be affected by AD pathology so we might expect that there would be early functional changes in anterior hippocampus before posterior regions [Braak et al., 1993; Small et al., 2011; Thal et al., 2002].”
BackgroundSelf-citationDiagnosis of Alzheimer’s Disease with [18F]PET in Mild and Asymptomatic Stages
Drzezga, A. E. (2009) · Behavioural Neurology · doi:10.1155/2009/276026 · Cited by 48
Linking vascular disorders and Alzheimer's disease: Potential involvement of BACE1
Cole, S. L., & Vassar, R. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.012 · Cited by 43
Apolipoprotein E ε4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults
Pomara, N., Willoughby, L. M., Wesnes, K. A., Greenblatt, D. J., & Sidtis, J. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.209 · Cited by 41
The presence of apoE4, not the absence of apoE3, contributes to AD pathology
Teter, B., Raber, J., Nathan, B., & Crutcher, K. A. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4305 · Cited by 37
“In cognitively normal individuals, those with ε 4 show reduced parietal, temporal, cingulate metabolism and longitudinal decline (PET) [78], increased subjective impairment [77], and increased activation during recall (fMRI) [78].”
Neural Metabolic Networks: Key Elements of Healthy Brain Function
Madrer, N., Perera, N. D., Uccelli, N. A., Abbondanza, A., Andersen, J. V., Carsana, E. V., Demmings, M. D., Fernandez, R. F., de Fragas, M. G., Gbadamosi, I., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70084 · Cited by 37
“Brain glucose hypometabolism is a clinical hallmark of AD and can be observed several years before clinical symptoms emerge (Minoshima et al. 1997; Mosconi 2005; Mosconi et al. 2009; Small et al. 2000).”
Lancaster, T. M., Brindley, L. M., Tansey, K. E., Sims, R. C., Mantripragada, K., Owen, M. J., Williams, J., & Linden, D. E. J. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.012 · Cited by 36
Peng, K. Y., Mathews, P. M., Levy, E., & Wilson, D. A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.12.004 · Cited by 35
“…versus noncarriers prior to the onset of cognitive decline within diverse brain regions (such as in hippocampi and specific regions of cortex) (Small et al., 2000; Reiman et al., 2004; Bookheimer and Burggren, 2009; Filippini et al., 2009; Dennis et al., 2010; Sheline et al., 2010; Brown et…”
BackgroundIron metabolism in diabetes-induced Alzheimer’s disease: a focus on insulin resistance in the brain
Chung, J. Y., Kim, H.-S., & Song, J. (2018) · BioMetals · doi:10.1007/s10534-018-0134-2 · Cited by 40
Early detection of Alzheimer's disease: An fMRI marker for people at risk?
Wagner, A. D. (2000) · Nature Neuroscience · doi:10.1038/79904 · Cited by 37
Amyloid-plaque imaging in early and differential diagnosis of dementia
Drzezga, A. E. (2010) · Annals of Nuclear Medicine · doi:10.1007/s12149-009-0330-9 · Cited by 41
“This includes combination of imaging and non-imaging biomarkers [19, 24, 82–86] as well as the combination of different imaging procedures [25, 87–90].”
MethodBiological Markers in Alzheimer Disease
Neugroschl, J. A., & Davis, K. L. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200211000-00005 · Cited by 42
Altered Prefrontal Brain Activity in Persons at Risk for Alzheimer’s Disease: An fMRI Study
Elgh, E., Larsson, A., Eriksson, S., & Nyberg, L. H. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203008810 · Cited by 39
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.